Physician profile
Patricia Davis
NPI 1356994685
$2,747.11
in general payments reported to CMS, 2019-2025
30 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $769 · 2023: $577 · 2024: $229 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,885 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,884.52 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $719.89 | 2022-2025 | |
| Astellas Pharma US INC | $272.32 | 2022-2023 | Myrbetriq, Veozah |
| Astrazeneca Pharmaceuticals Lp | $222.03 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Teva Pharmaceuticals USA, INC. | $167.00 | 2024-2025 | Austedo Xr, Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.52 | 2025 | Jardiance |
| Lilly USA, LLC | $136.16 | 2022-2025 | Zepbound, Mounjaro |
| Axsome Therapeutics, INC. | $110.52 | 2024-2025 | Auvelity |
| Novo Nordisk INC | $107.82 | 2022-2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $96.55 | 2024-2025 | Trintellix |
| Xeris Pharmaceuticals, INC. | $79.81 | 2023-2025 | Gvoke Hypopen, Keveyis |
| E.R. Squibb & Sons, L.L.C. | $78.02 | 2022-2023 | Eliquis |
| Amgen INC. | $69.81 | 2022-2023 | Repatha, Otezla |
| Scilex Pharmaceuticals INC. | $68.75 | 2023-2024 | Ztlido |
| Vanda Pharmaceuticals INC. | $60.83 | 2025 | Fanapt |
| Sage Therapeutics, LLC | $35.70 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $33.70 | 2022 | |
| Verona Pharma, INC. | $32.92 | 2025 | Ohtuvayre |
| Pfizer INC. | $32.91 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $32.83 | 2025 | Gemtesa |
| Exact Sciences Corporation | $32.26 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $31.98 | 2023-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $31.04 | 2025 | |
| Phathom Pharmaceuticals, INC. | $30.80 | 2025 | Voquezna |
| Dexcom, INC. | $24.77 | 2025 | Dexcom G6 Transmitter |
| Tonix Medicines, INC. | $19.73 | 2025 | Tonmya |
| Otsuka America Pharmaceutical, INC. | $18.51 | 2023 | Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.03 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.36 | 2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $14.40 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.14 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.